The Centre Territorial d’Information Pharmaceutique d’Avis (CTIAP for its French acronym) concluded that none of the four vaccines implemented in France are safe or effective. They all received emergency use authorization with insufficient clinical evidence and therefore demanded their immediate suspension.
CTIAP, which is linked to the Cholet public hospital in western France, recently published a report showing that the vaccines used against CCP Viruses underwent insufficient clinical testing. Also, the quality of the active substances, their “excipients—some of which are new,” and the manufacturing processes are deficient.
Dr. Catherine Frade leads the research team, a renowned pharmacist who worked on public data reported by the European Medicines Agency (EMA) regarding injections from Pfizer, Moderna, AstraZeneca, and Janssen (Johnson & Johnson).
The first warning published in the report is that all these products have only temporary marketing authorizations (MA). Besides, they are all subject to further studies until 2024, making it almost impossible to complete them given the accelerated way vaccines are being distributed.